文献速递腹部技术与安全USCTMR

全氟丁烷增强超声改良标准与CT/MRI LI-RADS v2018诊断高危患者HCC的个体内比较

Intraindividual Comparison of Contrast-Enhanced Ultrasound Using Perfluorobutane With Modified Criteria Versus CT/MRI LI-RADS Version 2018 for Diagnosing HCC in High-Risk Patients.
PubMed 文献 · AJR Am J Roentgenol · 2022-11-16

回顾性纳入171例高危患者,对比全氟丁烷增强超声改良LI-RADS标准与CT/MRI LI-RADS v2018诊断HCC的性能。两者LR-5的敏感度(92.1% vs 89.5%)、特异度(87.7% vs 84.2%)和准确率(90.6% vs 87.7%)无显著差异(p>.05)。研究支持全氟丁烷增强超声改良标准用于高危患者HCC诊断。

要点

  • 全氟丁烷增强超声改良标准将Kupffer期缺损的病灶归为LR-5,可提高HCC诊断敏感度。
  • 与CT/MRI LI-RADS v2018相比,改良CEUS标准诊断HCC的敏感度、特异度和准确率无显著差异。
  • 部分仅被CT/MRI评为LR-4或LR-M的病灶,经改良CEUS标准可正确升级为LR-5(HCC)。

核心结论

  • 全氟丁烷增强超声改良标准与CT/MRI LI-RADS v2018诊断HCC的LR-5性能无显著差异。

研究设计与样本

  • 回顾性研究纳入171例高危患者(140男,31女,平均年龄54±12岁),均经病理证实并有CEUS和CT/MRI检查。
  • 采用匹配算法按1:2选择HCC与非HCC患者,两名读者用全氟丁烷CEUS改良LI-RADS v2017标准评估,另两名读者用CT/MRI LI-RADS v2018评估,各自共识。

关键影像表现/征象

  • 全氟丁烷CEUS改良标准基于Kupffer期缺损将部分病灶从LR-4或LR-M升级为LR-5。
  • CT/MRI仅评为LR-4的6个病灶中,改良CEUS将1个评为LR-3(良性),5个评为LR-5(均为HCC)。
  • CT/MRI仅评为LR-M的7个病灶中,改良CEUS将1个评为LR-3(非HCC恶性),6个评为LR-5(均为HCC)。

诊断标准与关键数值

  • 全氟丁烷CEUS改良标准:Kupffer期缺损可将特定病灶归为LR-5而非LR-4或LR-M。
  • 改良CEUS标准LR-5诊断HCC的敏感度92.1%、特异度87.7%、准确率90.6%。
  • CT/MRI LI-RADS v2018 LR-5诊断HCC的敏感度89.5%、特异度84.2%、准确率87.7%。
  • 两种方法敏感度、特异度、准确率差异均无统计学意义(p>.05)。

临床应用与阅片要点

  • 高危患者HCC诊断可应用全氟丁烷CEUS改良标准,尤其当CT/MRI评为LR-4或LR-M时。
  • 注意Kupffer期缺损是改良标准升级为LR-5的关键征象,需规范采集Kupffer期图像。

局限性

  • 回顾性单中心设计,样本量有限,可能存在选择偏倚。
  • 采用匹配算法(HCC与非HCC 2:1)可能影响诊断性能的外推。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. Previously proposed modifications to LI-RADS criteria for contrast-enhanced ultrasound (CEUS) performed using perfluorobutane contrast agent yielded increased sensitivity for hepatocellular carcinoma (HCC) without a significant decrease in specificity. OBJECTIVE. The purpose of our study was to compare the diagnostic performance of CEUS with perfluorobutane using modified LI-RADS criteria versus contrast-enhanced CT or MRI using LI-RADS version 2018 (v2018) for characterizing lesions as HCC in high-risk patients. METHODS. This retrospective study included 171 patients (140 men, 31 women; mean age, 54 ± 12 [SD] years) at high-risk for HCC with a pathologically confirmed liver observation evaluated by both CEUS using perfluorobutane and contrast-enhanced CT or MRI between March 2020 and May 2021. A matching algorithm was used to select two patients with HCC for each patient with a non-HCC lesion. Two readers evaluated observations using previously proposed modifications to CEUS LI-RADS version 2017 that classify certain observations as LR-5 rather than as LR-4 or LR-M on the basis of the presence of Kupffer phase defect after perfluorobutane administration; two different readers evaluated observations using CT/MRI LI-RADS v2018. Each reader pair reached consensus. Diagnostic performance was evaluated. RESULTS. A total of 114 patients had HCC, 43 had a non-HCC malignancy, and 14 had a benign lesion. Modified CEUS criteria using perfluorobutane and CT/MRI LI-RADS v2018 showed no significant difference (p > .05) in sensitivity (92.1% vs 89.5%), specificity (87.7% vs 84.2%), or accuracy (90.6% vs 87.7%) of LR-5 for diagnosis of HCC. Of six observations assessed as LR-4 only by CT/MRI LI-RADS v2018, modified CEUS criteria using perfluorobutane assessed one as LR-3 (benign lesion) and five as LR-5 (all HCC). Of seven observations assessed as LR-M only by CT/MRI LI-RADS v2018, modified CEUS criteria using perfluorobutane assessed one as LR-3 (non-HCC malignancy) and six as LR-5 (all HCC). Eight of 12 observations assessed as LR-5 only by CT/MRI LI-RADS v2018 and 11 of 13 observations assessed as LR-5 only by modified CEUS criteria using perfluorobutane were HCC. CONCLUSION. The diagnostic performance of LR-5 for HCC diagnosis was not significantly different between modified CEUS criteria using perfluorobutane and CT/MRI LI-RADS v2018. CLINICAL IMPACT. The findings support the application of modified CEUS criteria using perfluorobutane for diagnosing HCC in high-risk patients.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Li, Mao, Wang, et al. Intraindividual Comparison of Contrast-Enhanced Ultrasound Using Perfluorobutane With Modified Criteria Versus CT/MRI LI-RADS Version 2018 for Diagnosing HCC in High-Risk Patients. AJR Am J Roentgenol. 2022. PMID: 36382914. doi:10.2214/AJR.22.28420

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。